Spero Therapeutics Stock Today
| SPRO Stock | USD 1.13 0.02 1.74% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Spero Therapeutics is selling at 1.13 as of the 27th of November 2024; that is 1.74 percent decrease since the beginning of the trading day. The stock's open price was 1.15. Spero Therapeutics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Spero Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of November 2017 | Category Healthcare | Classification Health Care |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. The company has 54.52 M outstanding shares of which 625.19 K shares are at this time shorted by private and institutional investors with about 2.08 trading days to cover. More on Spero Therapeutics
Moving together with Spero Stock
| 0.68 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.66 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.71 | INKT | Mink Therapeutics | PairCorr |
Moving against Spero Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Spero Stock Highlights
| President | Timothy Keutzer | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsSpero Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Spero Therapeutics' financial leverage. It provides some insight into what part of Spero Therapeutics' total assets is financed by creditors.
| |||||
Spero Therapeutics (SPRO) is traded on NASDAQ Exchange in USA. It is located in 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 and employs 46 people. Spero Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.61 M. Spero Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.52 M outstanding shares of which 625.19 K shares are at this time shorted by private and institutional investors with about 2.08 trading days to cover.
Spero Therapeutics currently holds about 45.4 M in cash with (32.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Spero Therapeutics Probability Of Bankruptcy
Ownership AllocationSpero Therapeutics shows a total of 54.52 Million outstanding shares. Spero Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Spero Ownership Details
Spero Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 130.5 K | |
| Dafna Capital Management Llc | 2024-09-30 | 125 K | |
| Northern Trust Corp | 2024-09-30 | 111.5 K | |
| Millennium Management Llc | 2024-06-30 | 98.5 K | |
| Citadel Advisors Llc | 2024-09-30 | 81.4 K | |
| Two Sigma Securities, Llc | 2024-06-30 | 67.7 K | |
| Man Group Plc | 2024-09-30 | 38.5 K | |
| Mackenzie Investments | 2024-09-30 | 31.9 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 28.6 K | |
| Anson Funds Management Lp | 2024-09-30 | 3.8 M | |
| Vanguard Group Inc | 2024-09-30 | 1.8 M |
Spero Therapeutics Historical Income Statement
Spero Stock Against Markets
Spero Therapeutics Corporate Management
| Satyavrat CFA | CFO Treasurer | Profile | |
| James Brady | Chief Officer | Profile | |
| Ted Jenkins | VP Relations | Profile | |
| Ian Critchley | Head Microbiology | Profile | |
| Susannah Walpole | Head Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share 2.223 | Quarterly Revenue Growth 2.754 | Return On Assets 0.1048 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.